Download Image
    
Share
  
Post
Atilotrelvir for COVID-19
1 study with >1,000 patients
Significantly lower risk for recovery and viral clearance.
COVID-19 Atilotrelvir studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies 13% Viral clearance 25% RCTs 13% Early 13% Favorsatilotrelvir Favorscontrol
Atilotrelvir was adopted in 1 country.
Dec 1
 Covid Analysis Atilotrelvir for COVID-19: real-time meta analysis of 1 study
Significantly lower risk is seen for recovery and viral clearance. Meta analysis using the most serious outcome reported shows 13% [1‑23%] lower risk. Currently there is very limited data, with only one study to date. No treatm..
May 31
2024
 Lu et al., eClinicalMedicine, doi:10.1016/j.eclinm.2024.102582 Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
13% faster recovery (p=0.03) and 25% faster viral clearance (p<0.0001). RCT 1,213 outpatients with mild-to-moderate COVID-19 in China showing a shorter time to sustained recovery and faster viral clearance with GST-HG171 (atilotrelvir) plus ritonavir.